Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:ALBONASDAQ:RNANASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.98+2.0%$16.38$13.40▼$25.23$3.68B0.471.93 million shs1.67 million shsALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsRNAAvidity Biosciences$30.58-0.7%$29.09$21.51▼$56.00$3.69B11.43 million shs455,159 shsZLABZai Lab$31.32-3.6%$31.63$16.01▼$39.77$3.46B1.04867,042 shs1.02 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.00%-1.26%+50.00%+10.18%+38.94%ALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%RNAAvidity Biosciences-0.75%+0.76%-0.33%-1.74%+3.24%ZLABZai Lab-3.63%+1.26%-6.84%-7.28%+55.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.4083 of 5 stars3.32.00.00.03.94.21.3ALBOAlbireo PharmaN/AN/AN/AN/AN/AN/AN/AN/ARNAAvidity Biosciences1.939 of 5 stars4.50.00.00.02.60.80.0ZLABZai Lab2.6665 of 5 stars3.43.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.64Moderate Buy$26.8322.08% UpsideALBOAlbireo Pharma 0.00N/AN/AN/ARNAAvidity Biosciences 3.00Buy$66.38117.09% UpsideZLABZai Lab 2.75Moderate Buy$47.3751.23% UpsideCurrent Analyst Ratings BreakdownLatest ALBO, RNA, ACAD, and ZLAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.00 ➝ $35.005/20/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $24.005/19/2025ACADACADIA PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.005/19/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/19/2025ACADACADIA PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.00 ➝ $26.005/19/2025ACADACADIA PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $28.005/19/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $30.005/19/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $32.005/16/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/12/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $68.005/7/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$996.28M3.69N/AN/A$2.63 per share8.36ALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85RNAAvidity Biosciences$8.93M412.85N/AN/A$6.76 per share4.52ZLABZai Lab$418.33M8.26N/AN/A$8.05 per share3.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M$1.3728.1828.92N/A13.83%25.83%14.71%8/5/2025 (Estimated)ALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/ARNAAvidity Biosciences-$212.22M-$3.00N/AN/AN/A-2,772.45%-27.66%-24.56%8/8/2025 (Estimated)ZLABZai Lab-$334.62M-$2.49N/AN/AN/A-76.14%-36.97%-27.10%8/5/2025 (Estimated)Latest ALBO, RNA, ACAD, and ZLAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 million2/27/2025Q4 2024ZLABZai Lab-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AALBOAlbireo PharmaN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.292.11ALBOAlbireo PharmaN/A6.326.23RNAAvidity BiosciencesN/A17.7617.76ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ALBOAlbireo Pharma94.25%RNAAvidity BiosciencesN/AZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ALBOAlbireo Pharma6.90%RNAAvidity Biosciences3.83%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million119.30 millionOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableRNAAvidity Biosciences190120.52 million114.92 millionOptionableZLABZai Lab1,950110.33 million94.24 millionOptionableALBO, RNA, ACAD, and ZLAB HeadlinesRecent News About These CompaniesZai Lab Limited: Banking On Chinese Pharma GrowthMay 22 at 11:43 AM | seekingalpha.comWoodline Partners LP Has $46.09 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 22 at 6:18 AM | marketbeat.comPoint72 Asset Management L.P. Purchases 270,136 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 22 at 4:42 AM | marketbeat.com43,178 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Lazard Asset Management LLCMay 22 at 4:15 AM | marketbeat.comVestal Point Capital LP Invests $7.86 Million in Zai Lab Limited (NASDAQ:ZLAB)May 21 at 8:14 AM | marketbeat.comZai Lab gets FDA fast track status for lung cancer treatmentMay 19, 2025 | msn.comRTW Investments LP Takes Position in Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 233,103 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comLMR Partners LLP Makes New Investment in Zai Lab Limited (NASDAQ:ZLAB)May 17, 2025 | marketbeat.comMPM Bioimpact LLC Purchases Shares of 800,000 Zai Lab Limited (NASDAQ:ZLAB)May 16, 2025 | marketbeat.comYing Du Sells 46,389 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockMay 16, 2025 | insidertrades.comZai Lab FY2025 EPS Estimate Increased by Cantor FitzgeraldMay 16, 2025 | marketbeat.comCantor Fitzgerald Expects Increased Earnings for Zai LabMay 15, 2025 | americanbankingnews.comJanus Henderson Group PLC Trims Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Sells 23,731 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 14, 2025 | marketbeat.comZai Lab Limited (ZLAB) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comThe Manufacturers Life Insurance Company Purchases 39,294 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 11, 2025 | marketbeat.comZai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2025 | finance.yahoo.comBridgefront Capital LLC Acquires Shares of 11,303 Zai Lab Limited (NASDAQ:ZLAB)May 10, 2025 | marketbeat.comBayesian Capital Management LP Takes $405,000 Position in Zai Lab Limited (NASDAQ:ZLAB)May 10, 2025 | marketbeat.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Zai Lab Limited Stock?May 9, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Moderna Stock Looks Ripe for a Short SqueezeBy Chris Markoch | May 22, 2025View Moderna Stock Looks Ripe for a Short SqueezeHomebuilders: Oversold, Undervalued, and Ready to Run?By Ryan Hasson | May 15, 2025View Homebuilders: Oversold, Undervalued, and Ready to Run?Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment?By Chris Markoch | May 15, 2025View Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment?ALBO, RNA, ACAD, and ZLAB Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.98 +0.43 (+2.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$21.62 -0.37 (-1.66%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Albireo Pharma NASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Avidity Biosciences NASDAQ:RNA$30.58 -0.23 (-0.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$30.57 -0.01 (-0.03%) As of 05/23/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Zai Lab NASDAQ:ZLAB$31.32 -1.18 (-3.63%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$31.28 -0.04 (-0.13%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
